|
As
of December 31, 2021, there were the following potentially dilutive securities that were excluded from diluted net loss per share
because their effect would be anti-dilutive:
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| Shares from the conversion of
Series B Preferred Stock not inclusive of accrued dividends |
|
|
235,774 |
|
| Shares from common stock options |
|
|
27,815 |
|
| Shares from common stock warrants |
|
|
37,083 |
|
| Shares from conversion of convertible notes
not inclusive of accrued interest |
|
|
75,625 |
|
| Shares from the conversion of debentures |
|
|
5,469 |
|
| Shares from the conversion of redeemable convertible
preferred stock (based upon an assumed conversion price at December 31, 2021 of $6.40
per share; inclusive of cumulative dividends which may be converted to shares of common stock under certain conditions) |
|
|
108,231 |
|
As
of December 31, 2020, there were the following potentially dilutive securities that were excluded from diluted net loss per share
because their effect would be anti-dilutive:
| Shares from the conversion
of Series B Preferred Stock |
|
|
43,906 |
|
| Shares from the conversion of Series E-1
Preferred Stock |
|
|
191,250 |
|
| Shares from common stock options |
|
|
11,715 |
|
| Shares from common stock warrants |
|
|
1,154 |
|
| Shares from the conversion of debentures |
|
|
15,625 |
|
| Shares that may be converted from Bridge Notes
(based upon an assumed conversion price at December 31, 2020 of $8.80
per share) |
|
|
164,468 |
|
| Shares from the conversion of redeemable convertible
preferred stock (based upon an assumed conversion price at December 31, 2020 of $8.80
per share; inclusive of cumulative dividends which may be converted to shares of common stock under certain conditions) |
|
|
68,182 |
|
|